Verekitug Achieves 79% NPS Response and 83% Symptom Score Improvement
UPB•Upstream Bio’s Phase 2 VIBRANT trial showed quarterly verekitug dosing achieved NPS improvements in 79% of participants versus 24% for placebo, with 72% improving nasal congestion and 83% reducing total symptom score. The therapy had no serious adverse events and Phase 3 trials are set to start in Q1 2027.
1. Phase 2 VIBRANT Trial Results
Upstream Bio enrolled 81 adults with severe, inadequately controlled CRSwNP in a randomized, double-blind Phase 2 trial of quarterly verekitug over 24 weeks. The treatment achieved a placebo-adjusted NPS reduction of −1.95 (p<0.0001) and a 79% responder rate for clinically meaningful NPS improvements versus 24% with placebo.
2. Key Secondary Endpoint Outcomes
Verekitug-treated participants showed a 72% one-point improvement in nasal congestion (versus 39% placebo; p=0.0046), an 83% ≥4-point reduction in total symptom score (versus 37% placebo; p<0.0001), and a 69% improvement in sense of smell (versus 21% placebo; p<0.0001). CT-based Lund–Mackay scores improved by ≥5 points in 78% of treated patients versus 12% on placebo.
3. Safety and Tolerability
The therapy was generally well tolerated with no serious adverse events reported. Verekitug treatment reduced the need for surgery or systemic corticosteroids by 76% compared with placebo (p=0.03), consistent with a favorable safety profile.
4. Phase 3 Development Plans
Building on VIBRANT’s robust efficacy and safety data, Upstream Bio plans to initiate registrational Phase 3 trials in CRSwNP and severe asthma in Q1 2027, targeting the TSLP receptor with convenient quarterly dosing to potentially advance the standard of biologic therapy.
